Progress in BRCA-Mutated Ovarian Cancer

被引：12
|
作者：
Spriggs, David R. [1 ,2 ]
Longo, Dan L.
机构：
[1] Harvard Med Sch, Dept Hematol Oncol, Boston, MA 02115 USA
[2] Harvard Med Sch, Dept Med, Boston, MA 02115 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2018年 / 379卷 / 26期
关键词：
CHEMOTHERAPY; BEVACIZUMAB;
D O I：
10.1056/NEJMe1812644
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2567 / 2568
页数：2
相关论文
共 50 条
  • [1] Olaparib for BRCA-mutated advanced ovarian cancer
    de Lartigue, Jane
    [J]. JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (06): : 206 - 208
  • [2] Olaparib for the treatment of BRCA-mutated advanced ovarian cancer
    Munroe, Marklie
    Kolesar, Jill
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (14) : 1037 - 1041
  • [3] Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
    Nicoletto, Maria Ornella
    Baldoni, Alessandra
    Cavallin, Francesco
    Grego, Andrea
    Falci, Cristina
    Nardin, Margherita
    Mammano, Enzo
    Lai, Eleonora
    Torri, Valter
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [4] Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated Ovarian Cancer
    Saleh, Naveed
    Copur, Mehmet Sitki
    [J]. ONCOLOGY-NEW YORK, 2019, 33 (07): : 293 - 294
  • [5] Doubling Down on BRCA-Mutated Cancer
    Hendrickson, Andrea E. Wahner
    Kaufmann, Scott H.
    Swisher, Elizabeth M.
    [J]. TRENDS IN CANCER, 2017, 3 (11): : 743 - 744
  • [6] Subtypes in BRCA-mutated breast cancer
    Sonderstrup, Ida Marie H.
    Jensen, Maj-Britt R.
    Ejlertsen, Bent
    Eriksen, Jens O.
    Gerdes, Anne-Marie
    Kruse, Torben A.
    Larsen, Martin J.
    Thomassen, Mads
    Laenkholm, Anne-Vibeke
    [J]. HUMAN PATHOLOGY, 2019, 84 : 192 - 201
  • [7] PARP inhibition in BRCA-mutated breast and ovarian cancers
    Chan, Stephen L.
    Mok, Tony
    [J]. LANCET, 2010, 376 (9737): : 211 - 213
  • [8] Talazoparib for BRCA-mutated advanced breast cancer
    Gunjur, Ashray
    [J]. LANCET ONCOLOGY, 2018, 19 (10): : E511 - E511
  • [9] Lurbinectedin for BRCA-mutated advanced breast cancer
    Gourd, Elizabeth
    [J]. LANCET ONCOLOGY, 2018, 19 (11): : E582 - E582
  • [10] Adjuvant Olaparib in BRCA-Mutated Breast Cancer
    Hoshi, Aoi
    Bando, Hiroko
    Sekine, Ikuo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15): : 1439 - 1440
12345